Study expected to enroll 24 patients with the option to enroll an additional 45 patients at the recommended Phase 2 doseProtocol calls for three ...
GlobalData on MSN
Lyell doses first patient in Phase III trial for LBCL
The trial aims to enrol nearly 200 patients per arm, including those with diffuse large B-cell lymphoma.
The FDA accepted filing for a new drug application (NDA) today for tirabrutinib for the treatment of adults with relapsed or refractory primary central nervous system lymphoma (R/R PCNSL), according ...
Please provide your email address to receive an email when new articles are posted on . It is a truism that, “If you operate, you will have complications.” Wise surgeons plan ahead to avoid ...
Secondary Neoplasms After Hematopoietic Cell Transplant for Sickle Cell Disease As of January 31, 2022, 157 patients were treated (median age, 64 years [range, 20‐83]; median of three [range, 2-11] ...
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with ...
Please provide your email address to receive an email when new articles are posted on . Case history: A 72-year-old patient underwent cataract surgery using the Crystalens accommodating lens implant ...
Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta® (axicabtagene ciloleucel) prescribing information removing the ...
A phase 3 trial finds pritelivir significantly improves cure rates for immunocompromised individuals with refractory HSV infections.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results